References
1. Sung H, Ferlay J, Siegel RL, et al. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 71(3):209-249.
2. Sciarra A, Park YN, Sempoux C. 2020. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Hum Pathol . 96:48-55.
3. Beaufrère A, Calderaro J, Paradis V. 2021. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol . 74(5):1212-1224.
4. Wang J, Li E, Yang H, et al. 2019. Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends. World J Surg Oncol . 17(1):43.
5. Fowler K, Saad NE, Brunt E, et al. 2015. Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy. Ann Surg Oncol . 22(13):4130-4137.
6. Ma MC, Chen YJ, Chiu TJ, et al. 2018. Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. BMC Cancer . 18(1):227.
7. Yoon YI, Hwang S, Lee YJ, et al. 2016. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Gastrointest Surg . 20(2):411-420.
8. Yin X, Zhang BH, Qiu SJ, et al. 2012. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol . 19(9):2869-2876.
9. Garancini M, Goffredo P, Pagni F, et al. 2014. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.Liver Transpl . 20(8):952-959.
10. Trikalinos NA, Zhou A, Doyle MBM, et al. 2018. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience.J Natl Compr Canc Netw . 16(10):1193-1199.
11. Kobayashi S, Terashima T, Shiba S, et al. 2018. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci . 109(8):2549-2557.
12. Salimon M, Prieux-Klotz C, Tougeron D, et al. 2018. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer . 118(3):325-330.
13. Finn RS, Qin S, Ikeda M, et al. 2020. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med . 382(20):1894-1905.
14. Maesaka K, Sakamori R, Yamada R, et al. 2021. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatol Res .
15. Hiraoka A, Kumada T, Tada T, et al. 2021. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.Hepatol Res .
16. Wang JH, Chen YY, Kee KM, et al. 2022. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. Cancers (Basel) . 14(2).
17. Hack SP, Spahn J, Chen M, et al. 2020. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.Future Oncol . 16(15):975-989.
18. Siegel AB, Cohen EI, Ocean A, et al. 2008. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol . 26(18):2992-2998.
19. Boige V, Malka D, Bourredjem A, et al. 2012. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.Oncologist . 17(8):1063-1072.
20. Hatanaka T, Hiraoka A, Tada T, et al. 2022. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research . n/a(n/a).
21. Kudo M, Izumi N, Kokudo N, et al. 2022. Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013). Hepatol Res . 52(1):5-66.
22. Jarnagin WR, Weber S, Tickoo SK, et al. 2002. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer . 94(7):2040-2046.
23. Allen RA, Lisa JR. 1949. Combined liver cell and bile duct carcinoma. Am J Pathol . 25(4):647-655.
24. Zhou YM, Zhang XF, Wu LP, Sui CJ, Yang JM. 2014. Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.World J Gastroenterol . 20(35):12615-12620.